Table 3.
Factors associated with successful conversion surgery in 94 patients who received conversion therapy for initially unresectable HCC.
| Univariate | Multivariate(Model 1)# | Multivariate(Model 2)# | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | OR | 95% CI | P | ||
| Age, y | > 60 vs ≦ 60 | 0.662 | 0.193 – 2.274 | 0.513 | ||||||
| Sex | Male vs Female | 2.138 | 0.229 – 19.968 | 0.563 | ||||||
| HBsAg-positive | Yes vs No | 1.230 | 0.296 – 5.117 | 0.776 | ||||||
| Tumor size, cm | > 10 vs ≦ 10 | 0.375 | 0.150 – 0.939 | 0.036 | 0.495 | 0.171 – 1.434 | 0.195 | 0.436 | 0.158– 1.198 | 0.107 |
| Tumor number | multiple vs single | 0.637 | 0.270 – 1.503 | 0.303 | ||||||
| PVTT | Yes vs No | 0.771 | 0.328– 1.815 | 0.552 | ||||||
| Macrovascular invasion | Yes vs No | 0.590 | 0.249 – 1.399 | 0.231 | ||||||
| BCLC stage | Stage C vs A/B | 0.409 | 0.169 – 0.990 | 0.047 | 0.538 | 0.187– 1.548 | 0.250 | 0.414 | 0.153 – 1.120 | 0.082 |
| AFP, ng/mL | > 400 vs ≦ 400 | 0.550 | 0.231 – 1.308 | 0.176 | 0.478 | 0.169 – 1.347 | 0.163 | 0.506 | 0.191 – 1.344 | 0.172 |
| SIRI | > 1.38 vs ≦ 1.38 | 0.378 | 0.156 – 0.918 | 0.032 | 0.459 | 0.165 – 1.276 | 0.136 | 0.454 | 0.168 – 1.229 | 0.120 |
| Platelet count,×109/L | > 100 vs≦ 100 | 2.719 | 0.304 – 24.325 | 0.371 | ||||||
| ALT, U/L | > 40 vs ≦ 40 | 0.992 | 0.420 – 2.344 | 0.985 | ||||||
| AST, U/L | > 40 vs ≦ 40 | 0.642 | 0.202 – 2.042 | 0.453 | ||||||
| Ascites | Yes vs No | 0.134 | 0.017 – 1.085 | 0.060 | 0.189 | 0.020 – 1.767 | 0.144 | 0.284 | 0.031 – 2.566 | 0.262 |
| NLR | > 2.82 vs ≦ 2.82 | 0.463 | 0.193 – 1.109 | 0.084 | ||||||
| PLR | > 146vs ≦ 146 | 0.463 | 0.193 – 1.109 | 0.084 | ||||||
| ALBI grade | Grade1 vs 2/3 | 0.698 | 0.172 – 2.836 | 0.615 | ||||||
| ECOG PS | 0 vs 1 | 1.790 | 0.740 – 4.329 | 0.197 | ||||||
| Early AFP response * | Yes vs No | 1.548 | 0.637 – 3.765 | 0.335 | – | – | – | 1.803 | 0.654 – 4.972 | 0.255 |
| Early tumor response† | Yes vs No | 9.474 | 2.072– 43.309 | 0.004 | 10.296 | 2.076 – 51.063 | 0.004 | – | – | – |
AFP, alpha fetoprotein; HCC, hepatocellular carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; ALBI grade, albumin-bilirubin grade; ALT, alanine aminotransferase; NA, not adopted; AST, aspartate aminotransferase; BCLC stage, Barcelona-Clinic liver cancer stage; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SIRI, systemic inflammation response index; CI, confidence interval; OR, odds ratio; PVTT, portal vein tumor thrombosis.
*Early AFP response: AFP reduced > 75% from baseline serum level at first follow-up.
†Early tumor response: Achievement of complete response (CR) and partial response (PR) using mRECIST at first follow-up.
Model 1 did not include early AFP response into multivariate analysis to avoid collinearity.
Model 2 did not include early tumor response into multivariate analysis to avoid collinearity.
The bold values denote statistically significant results of the multivariate analysis.